Analysis of the Current Situation of Psychotropic Drug Use among Children in China
ZHANG Xin-yan1, HU Xiao-wen1, ZHAO Yu-xuan1, NIE Xiao-yan1,2*, SHI Lu-wen1,2
1. Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; 2. International Research Center for Medicinal Administration, Peking University, Beijing 100191, China
Abstract：OBJECTIVE To investigate the prevalence and use patterns of psychotropic drugs in Chinese children and provide a reference for promoting the rational use of psychotropic drugs in children. METHODS Based on the national survey on the medical service utilization of basic medical insurance beneficiaries, a cross-sectional study was conducted to analyze the prevalence, drug utilization patterns, and polypharmacy among children in China. RESULTS The database included 757639 insured children, among whom 11898 were observed with at least one psychotropic drug use record in the database. The prevalence of psychotropic drug use was 15.7‰. Among different psychotropic classes, the prevalence of sedative-hypnotic drugs was the highest (11.8‰), followed by anxiolytics (3.0‰), antipsychotics (1.6‰), antidepressants (0.6‰) and mood stabilizers (0.1‰). Among them, olanzapine (16.2%), sertraline (45.6%), midazolam (76.9%), tandospirone (63.4%) and lithium (100.0%) were the most commonly used drugs in each psychotropic class, respectively. Among the 11898 children, 19.5% received psychotropic polypharmacy treatment. CONCLUSION This study shows that mental disorders among Chinese children need attention. The dynamic monitoring and evaluation system of drugs in children should be strengthened to improve the under-treatment and inappropriate medication in clinical practice.
张鑫炎, 胡晓雯, 赵宇璇, 聂小燕, 史录文. 我国儿童精神药物使用现状分析[J]. 中国药学杂志, 2023, 58(10): 933-938.
ZHANG Xin-yan, HU Xiao-wen, ZHAO Yu-xuan, NIE Xiao-yan, SHI Lu-wen. Analysis of the Current Situation of Psychotropic Drug Use among Children in China. Chinese Pharmaceutical Journal, 2023, 58(10): 933-938.
POLANCZYK G V, SALUM G A, SUGAYA L S, et al. Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents[J]. J Child Psychol Psychiatry, 2015, 56(3):345-365.
[2]
ANSARI H, SANTIAGO-JIMéNEZ M, SAAB H, et al. Association between comorbid psychiatric disorders and hospital resource use in physically ill pediatric inpatients: a case-matched analysis[J]. J Am Acad Child Adolesc Psychiatry, 2021, 60(3):346-354.
[3]
ZIMA B T. Editorial: the cost of comorbid child psychiatric disorders: a national call to achieve the triple aim for child mental health care[J]. J Am Acad Child Adolesc Psychiatry, 2021, 60(3):336-337.
[4]
ZUBRICK S R, HAFEKOST J, JOHNSON S E, et al. Suicidal behaviours: prevalence estimates from the second australian child and adolescent survey of mental health and wellbeing[J]. Aust N Z J Psychiatry, 2016, 50(9):899-910.
[5]
ZUBRICK S R, HAFEKOST J, JOHNSON S E, et al. Self-harm: prevalence estimates from the second australian child and adolescent survey of mental health and wellbeing[J]. Aust N Z J Psychiatry, 2016, 50(9):911-921.
[6]
OERBECK B, OVERGAARD K R, HJELLVIK V, et al. The use of antidepressants, antipsychotics, and stimulants in youth residential care[J]. J Child Adolesc Psychopharmacol, 2021,31(5):350-357.
[7]
RASMUSSEN L, BILENBERG N, THRANE J M, et al. Use of tic-suppressing medication and other psychotropic drugs in children and adolescents with newly diagnosed tic disorders in Denmark[J]. J Child Adolesc Psychopharmacol, 2020,30(8):476-485.
[8]
DINNISSEN M, DIETRICH A, VAN DER MOLEN J H, et al. Prescribing antipsychotics in child and adolescent psychiatry: guideline adherence[J]. Eur Child Adolesc Psychiatry, 2020,29(12):1717-1727.
[9]
LOPEZ-LEON S, LOPEZ-GOMEZ M I, WARNER B, et al. Psychotropic medication in children and adolescents in the united states in the year 2004 vs 2014[J]. Daru, 2018, 26(1):5-10.
[10]
BARCZYK Z A, RUCKLIDGE J J, EGGLESTON M, et al. Psychotropic medication prescription rates and trends for new zealand children and adolescents 2008-2016[J]. J Child Adolesc Psychopharmacol, 2020,30(2):87-96.
[11]
HOON D, TAYLOR M T, KAPADIA P, et al. Trends in off-label drug use in ambulatory settings: 2006-2015[J]. Pediatrics, 2019, 144(4).Doi: 10.1542/peds.2019-0896.
[12]
CHEN S, BARNER J C, CHO E. Trends in off-label use of antipsychotic medications among texas medicaid children and adolescents from 2013 to 2016[J]. J Manag Care Spec Pharm, 2021, 27(8):1035-1045.
[13]
CARTON L, COTTENCIN O, LAPEYRE-MESTRE M, et al. Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends[J]. Curr Pharm Des, 2015, 21(23):3280-3297.
[14]
BAILLY F, BELAID H. Suicidal ideation and suicide attempt associated with antidepressant and antiepileptic drugs: implications for treatment of chronic pain[J]. Joint Bone Spine, 2021,88(1):105005. Doi: 10.1016/j.jbspin.2020.04.016.
[15]
AMERICAN DIABETES ASSOCIATION, AMERICAN PSYCHIATRIC ASSOCIATION, AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes[J]. Diabetes Care, 2004, 27(2):596-601.
[16]
MAN K K C, SHAO S C, CHANG Y C, et al. Cardiovascular and metabolic risk of antipsychotics in children and young adults: a multinational self-controlled case series study[J]. Epidemiol Psychiatr Sci, 2021, 30:e65. Doi:10.1017/S2045796021000494.
[17]
ANAGNOSTOU E, AMAN M G, HANDEN B L, et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial[J]. JAMA Psychiatry, 2016, 73(9):928-937.
[18]
RAY W A, STEIN C M, MURRAY K T, et al. Association of antipsychotic treatment with risk of unexpected death among children and youths[J]. JAMA Psychiatry, 2019, 76(2):162-171.
[19]
LI F, CUI Y, LI Y, et al. Prevalence of mental disorders in school children and adolescents in china: diagnostic data from detailed clinical assessments of 17,524 individuals[J]. J Child Psychol Psychiatry, 2022, 63(1):34-46.
[20]
FANG H, EGGLESTON K, HANSON K, et al. Enhancing financial protection under China′s social health insurance to achieve universal health coverage[J]. BMJ, 2019, 365:l2378. Doi: 10.1136/bmj.l2378.
[21]
YU S, ZHANG Y, YAO Y, et al. Migraine treatment and healthcare costs: retrospective analysis of the china health insurance research association (CHIRA) database[J]. J Headache Pain, 2020, 21(1):53. Doi: 10.1186/s10194-020-01117-2.
[22]
LIU J C, AI J, LV L X, et al. Psychopharmacology(2nd edition)(精神药理学第2版)[M]. Beijing: People′s Medical Publishing House Co.,Ltd, 2016.
[23]
ARORA N, KNOWLES S, GOMES T, et al. Interprovincial variation in antipsychotic and antidepressant prescriptions dispensed in the canadian pediatric population[J]. Can J Psychiatry, 2016, 61(12):758-765.
[24]
WU Y Z,ZHENG Y, CUI Y H. Advances in research on factors affecting the outcome of childhood mental disorders[J]. J Clin Psychiatry, 2017, 2(27):134-136.
[25]
SIDORCHUK A, ISOMURA K, MOLERO Y, et al. Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: a total population register-linkage study[J]. PLos Med, 2018, 15(8):E1002635.
[26]
MONTI J M, DEBELLIS J, ALTERWAIN P, et al. Midazolam and sleep in insomniac patients[J]. Br J Clin Pharmacol, 1983, 16(Suppl.1):87S-88S.
[27]
INAGAKI T, MIYAOKA T, TSUJI S, et al. Adverse reactions to zolpidem: case reports and a review of the literature[J]. Prim Care Companion J Clin Psychiatry, 2010, 12(6). Doi: 10.4088/PCC.09r00849bro.
[28]
PALAGINI L, BIANCHINI C. Pharmacotherapeutic management of insomnia and effects on sleep processes, neural plasticity, and brain systems modulating stress: a narrative review[J]. Front Neurosci, 2022,16:893015. Doi: 10.3389/fnins.2022.893015.
[29]
TOHEN M, KRYZHANOVSKAYA L, CARLSON G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania[J]. Am J Psychiatry, 2007, 164(10):1547-1556.
[30]
BISHOP J R, PAVULURI M N. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia[J]. Neuropsychiatr Dis Treat, 2008, 4(1):55-68.
[31]
HAO J, LIU J. Risk of obesity and diabetes from anti-psychotic drugs[J]. Chin Pharm J(中国药学杂志), 2013, 48(11):934-936.
[32]
ROBERTSON H T, ALLISON D B. Drugs associated with more suicidal ideations are also associated with more suicide attempts[J]. PLoS One, 2009, 4(10):E7312. Doi: 10.1371/journal.pone.0007312.
[33]
EGGART V, CORDIER S, HASAN A, et al. Psychotropic drugs for the treatment of non-suicidal self-injury in children and adolescents: a systematic review and meta-analysis[J]. Eur Arch Psychiatry Clin Neurosci, 2022. Doi: 10.1007/s00406-022-01385-w.
[34]
LI K, ZHOU G, XIAO Y, et al. Risk of suicidal behaviors and antidepressant exposure among children and adolescents: a meta-analysis of observational studies[J]. Front Psychiatry, 2022, 13:880496.Doi: 10.3389/fpsyt.2022.880496.
[35]
HENGARTNER M P, AMENDOLA S, KAMINSKI J A, et al. Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: a systematic review and meta-analysis of observational studies[J]. J Epidemiol Community Health, 2021. Doi: 10.1136/jech-2020-214611.
[36]
ALTSHULER L, KIRIAKOS L, CALCAGNO J, et al. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review[J]. J Clin Psychiatry, 2001, 62(8):612-616.
[37]
ALTSHULER L, SUPPES T, BLACK D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up[J]. Am J Psychiatry, 2003, 160(7):1252-1262.
[38]
JACK R H, HOLLIS C, COUPLAND C, et al. Incidence and prevalence of primary care antidepressant prescribing in children and young people in england, 1998-2017: a population-based cohort study[J]. PLoS Med, 2020, 17(7):E1003215. Doi: 10.1371/journal.pmed.1003215.
[39]
COMER J S, OLFSON M, MOJTABAI R. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007[J]. J Am Acad Child Adolesc Psychiatry, 2010, 49(10):1001-1010.
[40]
CHEN H, PATEL A, SHERER J, et al. The definition and prevalence of pediatric psychotropic polypharmacy[J]. Psychiatr Serv, 2011, 62(12):1450-1455.
[41]
ZITO J M, DERIVAN A T, KRATOCHVIL C J, et al. Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring[J]. Child Adolesc Psychiatry Ment Health, 2008, 2(1):24. Doi: 10.1186/1753-2000-2-24.
[42]
CLEARE A, PARIANTE C M, YOUNG A H, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 british association for psychopharmacology guidelines[J]. J Psychopharmacol, 2015, 29(5):459-525.
[43]
MCCLELLAN J, STOCK S. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia[J]. J Am Acad Child Adolesc Psychiatry, 2013, 52(9):976-990.
[44]
RICHARDSON L P, LUDMAN E, MCCAULEY E, et al. Collaborative care for adolescents with depression in primary care: a randomized clinical trial[J]. JAMA, 2014, 312(8):809-816.
2023, Vol. 58 
